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Effect of pregnancy in patients with lupus nephropathy
JOHN P. HAYSLETT and ROBERT I. LYNN
Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut
Systemic lupus erythematosus (SLE) occurs pri-
marily in women during child-bearing years. The
possible influence of pregnancy on the underlying
activity of SLE has important implications for this
group of patients because of the threat of severe,
and even life threatening, exacerbations of disease,
and the possibility of a reduced likelihood of a suc-
cessful outcome for the product of conception. On
the basis of previous reports on large series of cas-
es, the relationship between SLE and pregnancy is
controversial [1-4]. Furthermore, although renal in-
volvement is a common feature of SLE and is a ma-
jor source of morbidity and death [5], the influence
of pregnancy on lupus nephropathy has not been as-
certained. Previous reports on the relationship be-
tween lupus nephropathy and pregnancy are diffi-
cult to analyze because, in general, few have de-
tailed information on the chronologic sequence of
nephropathy and pregnancy, and the type and se-
verity of the underlying renal histopathologic lesion
[1—3, 6—11]. Moreover, in some initial reports, cur-
rent modes of treatment were not available.
The present study was undertaken to character-
ize the clinical course of SLE in patients with lupus
nephropathy during pregnancy and postpartum. Be-
cause it seemed unlikely that sufficient clinical ma-
terials for analysis would be available to any single
clinic, or that a prospective study of pregnancy in
patients with SLE would be performed in the near
future, we conducted a survey of nephrologists with
an interest in lupus nephropathy, representing a
wide geographic distribution.
This analysis is derived from data obtained on 65
pregnancies by 47 patients with SLE reported from
13 centers. All patients manifested clinical signs of
lupus nephropathy at some time during the course
of their illness, and renal biopsy material was avail-
able in 77% of cases. Because lupus nephropathy
increases the morbidity associated with SLE, it
seems likely that any bias in selection of these cases
would favor those with greater severity. In addi-
207
tion, because these cases were obtained from mul-
tiple centers, the clinical material used in this analy-
sis tends to reflect the widely divergent attitudes to-
wards SLE and treatment modalities used to treat
this disease.
Methods
The survey was performed by sending a letter of
inquiry to 46 nephrology centers and individual
nephrologists with an interest in lupus nephropathy,
which asked each addressee whether he had de-
tailed information on one or more patients with
SLE during pregnancy that could be shared with the
survey. A detailed questionnaire was subsequently
sent to 22 individuals who returned a positive re-
sponse. The questionnaire requested information in
the following areas:
(1) Onset of SLE. Information was requested on
the date and age of patients at onset of SLE and
initial clinical manifestations, including signs of re-
nal involvement, urine analysis, serum creatinine,
creatinine clearance, and quantitative protein ex-
cretion. In addition, the results of the following
tests were requested: LE test, complement levels
(total hemolytic, C3, and C4), DNA antibody test,
and antinuclear antibody tests. Each respondent
was asked to provide the range of normal values for
his laboratory. Information on the date and results
of renal biopsy was obtained and included a detailed
description of findings by light and electron micros-
copy and immunofluorescent microscopy. Last, we
requested information on the use of drug therapy
and the response to treatment.
(2) Pregnancy. The following information was
asked about each pregnancy during three intervals
(6 months prior to conception, during pregnancy,
and 3 months following pregnancy [postpartum]):
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clinical manifestations, including renal status, sero-
logic parameters (as above), treatment, and re-
sponse to treatment. In addition, data were ob-
tained on the status of the product of conception,
medical complications at time of delivery, and
mode of delivery.
(3) Foliowup course. Information was obtained
on clinical manifestations since last delivery, renal
status, and serologic parameters. Recordings of
subsequent specific renal findings were made. Fi-
nally, each respondent was asked to provide com-
ments on the overall assessment of the relationship
of SLE to pregnancy for each individual patient.
The source of data for the survey is listed below
and indicates that they were obtained from 13 sep-
arate centers that returned completed question-
naires. In this analysis the following criteria and
definitions were used:
Definition of SLE. Patients were included when
signs and symptoms of disease and laboratory re-
suits conformed to the diagnostic criteria estab-
lished by the American Rheumatology Association
[12].
Extrarenal manifestations. Signs of systemic and
multisystem disease ascribable to SLE were classi-
fied as mild, moderate, or severe. Mild severity was
defined as manifestations that did not limit patient
activity. Moderate severity limited physical activity
to some degree, and severe activity described pa-
tients who were acutely ill and required hospital-
ization.
Renal status. A serum creatinine value of 1.5 mg/
dl or more indicated overt renal insufficiency, and a
protein excretion of> 300 mg/day was considered
abnormal. The nephrotic syndrome was defined as a
urine protein excretion > 3.0 g/day and a serum al-
bumin < 3.0 g/dl.
Serologic paraneters. Serologic parameters were
classified as abnormal when the results of at least
two different studies (complement, DNA antibody,
and antinuclear antibody titer) exceeded the normal
range of values.
Renal biopsy. The histopathologic classification
of renal lesions used in this analysis has been pre-
viously reported by our laboratory [13], and is a
modification of the Comerford and Cohen classifi-
cation [14]:
Type I is normal glomerular structure or a mild
proliferative lesion with no electron-dense deposits
found on ultrastructure examination. Type II is a
thickened capillary basement membrane with elec-
tron-dense deposits located in subepithelial loci;
mesangial deposits are also usually present. Type
III is a focal or diffuse proliferative glomerulone-
phritis of moderate or severe intensity, with sub-
endothelial electron-dense deposits. Mesangial and
occassionally subepithelial deposits may also be
present. This type of lesion is often associated with
exudation and focal areas of necrosis. Type lila is a
mild to moderate proliferative glomerulonephritis
with electron-dense deposits confined to the mesan-
gial area.
Exacerbation is defined as the appearance of
clinical extrarenal manifestations and/or signs of
renal disease following a period of remission, or an
increase in severity of extrarenal and/or renal mani-
festations in a patient with signs of disease activity.
An increase in extrarenal manifestations occurred
when severity changed from mild to moderate, or
from moderate to severe, whereas an increase in re-
nal manifestations was defined as a rise in the serum
creatinine concentration of at least 0.5 mg/dl and/or
an increase in urine protein excretion of 1.0 g/day.
Remission is complete absence of clinical signs or
symptoms of disease activity.
Status of product of conception is as follows:
full-term delivery, duration of pregnancy estimated
to be 37 or more weeks; abortus, delivery before
viability (< 500 g or < 21 weeks gestation); pre-
mature, delivery before 37 weeks gestation; still-
birth, fetal death after stage of viability was achieved
(>500 g or> 21 weeks gestation).
Results
This analysis was performed on clinical data ob-
tained from 13 centers on 65 pregnancies by 47 pa-
tients. The onset of SLE occurred during pregnancy
or postpartum in 9 pregnancies (14%). In the re-
maining 56 pregnancies, gestation occurred after
onset of SLE, and in these pregnancies clinical
manifestations of lupus nephropathy preceded con-
ception in 80%. One or more renal biopsies were
performed in 36 patients (77%). The average age at
onset of SLE was 20.4 years, and the mean duration
of followup from onset of disease was 8.9 years.
The clinical activity of SLE during a pregnancy
and 3 months postpartum is shown in Table 1.
These data demonstrate that the clinical course of
SLE was not adversely influenced by pregnancy in
34 pregnancies (6 1%) antedated by onset of SLE. In
22 pregnancies (39%), an exacerbation, either re-
lapse or worsening of disease activity, occurred
during gestation or postpartum. In contrast to pre-
vious reports, exacerbation was more common dur-
ing pregnancy than it was immediately following de-
livery [1, 8].
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Analysis of pregnancies occurring after onset of
SLE. Because previous reports suggest that the ac-
tivity of SLE immediately before and at onset of
pregnancy had an important influence on the course
of disease during gestation and postpartum [1, 4, 11],
individual pregnancies were classified as either
exhibiting (1) complete clinical remission or (2)
signs of clinical activity, during the 6-month interval
before conception. In this classification, clinical ac-
tivity was defined as any evidence of renal or multi-
system disease. Serologic changes were not used as
a criterion of clinical activity.
(1) Remission before pregnancy. There was no
evidence of disease activity within 6 months of con-
Table 1. SLE activity during pregnancy and 3 months
postpartum
Status of SLE during pregnancy
and postpartum Total
Unchanged
Sustained remission 21
Active throughout 10
Exacerbation at pregnancy
From remission at onset of pregnancy 6
From activity at onset of pregnancy 10
Exacerbation at 3 months postpartum
From remission at onset of pregnancy 4
From activity at onset of pregnancy 2
Remission from activity at onset of pregnancy
During pregnancy 3
During 3 months postpartum 0
First onset of SLE
During pregnancy 6
During 3 months postpartum 3
Total 65
ception in 31 pregnancies, and as shown in Table 2,
remission was sustained in 21 instances (68%). In 10
pregnancies (32%), an exacerbation occurred either
during gestation (6) or postpartum (4). The outcome
of the product of conception in this group is also
shown in Table 2. After exclusion of pregnancies
that were surgically interrupted, solely because of
the presence of SLE and not because of a preg-
nancy-associated complication, the incidence of
live births was 88%. Premature births did not ex-
ceed the expected rate of 8.2% recorded in a popu-
lation of healthy subjects [15]. Of the 3 spontaneous
abortions, 2 of these, occurring at 20 and 24 weeks,
respectively, represent a fetal loss above the ex-
pected rate [16]. Overall, therefore, the likelihood
of a successful outcome of pregnancy in patients in
remission at onset of gestation was reduced about
8% (2/24), and fetal deaths occurred exclusively in
patients who exhibited sustained remission. The ra-
tionale for surgical interruption in this group of
pregnancies, as well as in other parts of the study,
was concern for the possible adverse effect of preg-
nancy on SLE or possible harmful effects of cyto-
toxic agents. The activity of SLE was not adversely
affected by therapeutic abortions, as previously
suggested [1].
A summary of clinical data and renal biopsy re-
sults in individual patients is shown in Table 3.
Serologic studies were performed before concep-
tion in approximately one half of the group and, as
noted in Methods, were classified as abnormal
when the results of at least two tests (antinuclear
Remission sustained
Full-term deliveries
Spontaneous abortion
Therapeutic abortion
Total
Exacerbation at pregnancy or postpartum
Full-term delivery
Premature delivery
Live
Dead
Spontaneous abortion
Therapeutic abortion
Stillbirth
Total
Total
12
3
6
21
8
0
0
10
Severity unchanged
Full-term deliveries
Spontaneous abortion
Therapeutic abortion
Still birth
Total
Exacerbation at pregnancy or postpartum
Full-term delivery
Premature delivery
Live
Dead
Spontaneous abortion
Therapeutic abortion
Stillbirth
Total
Remission at pregnancy
Full-term delivery
Spontaneous abortion
Therapeutic abortion
Total
Total
6
2
10
7
0
0
3
12
SLE in remission prior to conception
Table 2. Effect of SLE activity 6 months before conception on clinical course during pregnancy and postpartum, and on outcome of
pregnancy
SLE clinically active prior to conception
3
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Table 3. Summary of clinical data of women with SLE in remission prior to conceptions
Past history
Onset
preg.
6 Months before pregnancy
Manifestations Serology
BUN/Creat.
mgldl
Urine
prot.
giday RxPatientb Manifestations Rx
Sustained remission
1 (2) Moderate Pred 2/67 None 15/— <0.3 Pred
extrarenal
5 Moderate Pred 6/76 None Inact —/1.0 <0.3 Pred
extrarenal Mustard
hematuria
8 (1) Severe Pred 7/75 None Act —/0.7 <0.3 Pred
extrarenal
(2) Prot. 1 to 2+ 10/76 None —/0.8 <0.3 Pred
15 (2) Moderate Pred 1/71 None —/0.8 <0.3 None
extrarenal
Prot. 2 to 3+
18 (2) Moderate Pred 12/74 None Act 0/0.9 0.2 Pred
extrarenal
(3) Prot. 2+ 5/77 None Inact <0.3 Pred
20 (2) Moderate None 1/78 None — — None
extrarenal
Prot. 2 to 3+
21(2) Moderate ACTH 7/65 None —/1.0 1 to2+ None
extrarenal
(3) Nephrotic 12/66 None — Pred
22 Moderate Pred 6/67 — None
extrarenal
Prot. 0.8 g/day
29 (1) Moderate Pred 2/71 None Inact 14/— <0.3 Pred
extrarenal Imur Imur
(2) Prot. 3.2 g/day /74 None Inact 15/— <0.3
37 Moderate Pred 11/75 None Act —/1.1 <0.3 Pred
extrarenal Imur Imur
Prot. 1.lg/day
40 (1) Moderate Pred 6/70 None inact —/0.7 <0.3 Pred
extrarenal Imur Imur
(2) Prot. 2.0 g/day 2/73 None Inact —/0.8 0.1 Pred
42 Moderate Pred 9/61 None —/1.0 1+ Pred
extrarenal
Prot. 2+
43 Mild Pred 11/74 None Act —/0.8 0.1 Pred
extrarenal Imur Imur
Prot. 2+
45 Moderate Pred 12/68 None Inact —/0.8 0.2 Pred
extrarenal Imur Imur
Nephrotic
49 (1) Moderate Pred 6/74 None Inact —/1.5 0.1 Pred
extrarenal Imur
(2) Prot. 2.Oglday 4/77 None Inact —/0.8 0.1 Pred
Exacerbation during pregnancy or postpartum
2 Moderate Pred 9/72 None — <0.3 Pred
extrarenal Imur
Prot. 2+
19 Severe Pred 7/71 None Inact —/1.5 0.2 Pred
extrarenal
Creat. 4.2 mg/dl
Prot. 0.6 g/day
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Table 3 (continued)
During pregnancy and postpartum
BP At
mm/Hg Rx delivery
Renal
biopsy CommentManifestations Serology
BUN/Creat
mg/dl
Urine
prot.
giday
Sustained remission
None 15/— <0.3 Pred FT 10/73 1972—73 flare, proteinuria
Type lIla >1976, remission— 1979
None Inact —/0.5 <0.3 Pied FT — Complete remission 1979
None —/1.0 <0.3 Pied TA
None —/0.8 <0.3 Pied TA Complete remission 1979
None 0/0.8 <0.3 None SA 1961 Subsequent flares
Type III
None 11/— 0.2 Pied FT 8/73
Type III
None Act —/0.8 0.4 Pied FT Complete remission 1979
None — — — None SA 6/77 Apparent remission
Type III
None Inact —/0.8 0.7 140 None FT 4/71-Type III
85 8/75-Type lila
None —/1.1 1+ Pied TA Creat, 1.6mg/di;
prot. 0.8g/day, 1975
None None SA 8/61
Type III Complete remission 1977
6/62
Type II
6/71
Type I
None Inact 14/— <0.3 Pied FT 5/70
Imur Type III
None Inact 15/— <0.3 — FT Complete remission 1979
None Act —/0.6 <0.3 135 Pied FT 4/75 Complete remission 1977
90 Imur Type III
None Inact —/0.8 0.1 110 Pied FT 3/67
60 Type III Complete remission 1979
None Inact —/1.0 0.1 115 Pied FT 4/72
60 Type lila
1/74
Type lila
7/77—Type I
None Inact —/0.9 1+ Pied TA 10/70 1967 Nephrotic, remission
Type III on Pied-Imur,
8/75 complete remission, 1975
Type lila
BP Act —/0.8 0.1 140 Pied TA 6/74 Persistent mild
100 Imur Type III extrarenal 1979
1976
Type II
None Inact 0/0.8 <0.3 115 Pred TA 1/68
60 Imur Type III
1/70 Renal failure 4 yr
Type II after pregnancy
None Inact —/0.9 0.1 120 Pied FT 8/68—Type II
70 9/71—Type lila
None Inact —/0.8 0.1 115 Pied FT 9/73—Type I Complete remission 1979
60
Exacerbation during pregnancy or postpartum
Nephrotic Act —/>6.0 9.0 150 Pred FT 5/73 Relapse 3rd trimester,
Renal > 100 Cytox Type lila complete remission 1979
failure
t BP Inact —/1.3 1.6 150 Pied FT 4/71 Preeclampsia trimester,
120 Type I complete remission 1978
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Table 3 (continued)
Past history Onset
preg. Manifestations
6 Months before pregnancy
Serology
BUN/Creat.
ing/dI
Urine
prot.
glday RxPatient5 Manifestations Rx
20 (3) Moderate None 2/79
Sustained remission
None — — — None
extrarenal
Hematuna
21 (1) Moderate ACTH 4/62 None — — — —
extrarenal
Nephrotic
25 (2) Moderate Pred 6/78 t BP Inact 0/0.7 1+ None
extrarenal
Nephrotic
Creat, 2.0 mg/dl
38 Moderate Pred 4/76 None Inact — <0.3 Pred
extrarenal
Prot. lto2+
17 Severe Pred 6/78 None — —/0.8 <0.3 Pred
extrarenal
50 Moderate Pred 8/68 None — 0/1.0 <0.3 None
extrarenal
15 (1) Moderate Pred 5/64 None — — — None
extrarenal
Prot. 2 to 3+
48 Moderate Pred 5/69 None — 12/— 0.1 None
extrarenal
Prot.lyo2+
a The following abbreviations are used; hx, history; preg, pregnancy; Bx, biopsy; Rx, treatment; BP, blood pressure; prot., urine
protein; Creat., serum creatinine; Pred, prednisone; Imur, Imuran; chioro, chloroquin; Inact, inactive or normal values; Act, active or
abnormal values; FT, full term delivery; SA, spontaneous abortion; TA, therapeutic abortion.b The number in parenthesis following some of the case numbers indicates the order of pregnancies in women with multiple births.
antibody, complement, and DNA antibody) ex-
ceeded normal values. Inspection of Table 3 dem-
onstrates that, in general, serologic parameters cor-
responded to clinical signs of disease activity.
Among pregnancies characterized by sustained re-
mission, clinical evidence of lupus nephropathy was
present at an earlier stage of the disease in 20 of 21
cases, and included nephrotic syndrome in 2 cases
and renal insufficiency in 1. In other cases, the pres-
ence of asymptomatic proteinuria or hematuria pro-
vided evidence of renal involvement. in 6 instances,
a diffuse glomerulonephropathy with subendothelial
deposits (type III) was found by renal biopsy 6
months or more before conception, and in 3 cases a
typle III lesion was demonstrated within 6 months
of pregnancy. In each of 8 cases in which additional
renal biopsies were subsequently performed, there
was histologic evidence of a reduction in the inflam-
matory response by light microscopy and transfor-
mation, by ultrastructure, to another histologic
classification due to loss of subendothelial deposits.
The initial renal biopsy revealed a type II and type I
lesion before pregnancy in 2 patients, respectively,
and 2 patients were shown to have a type lila lesion
on biopsy performed during subsequent followup.
Among 10 pregnancies characterized by ex-
acerbation during gestation or postpartum, there
was previous evidence of renal disease in 8 and re-
lapse involved signs of lupus nephropathy in all but
one pregnancy, including 3 cases of renal in-
sufficiency and 3 episodes of nephrotic syndrome.
Although the blood pressure recordings were not
available in all patients during pregnancy, hyper-
tension occurred in at least 7 of 10 pregnancies.
There were no patient deaths, and in the 8 cases
followed for more than 3 months after delivery,
there was a complete or partial reversal of the ex-
acerbation. Renal biopsy was performed in 8 pa-
tients and provided adequate tissue for analysis in
7. In 2 patients, a type III lesion was found 6
months or more before conception; 1 of these pa-
tients developed nephrotic syndrome and renal in-
sufficiency during pregnancy and was shown, by
biopsy in the first trimester, to have chronic glomer-
Lupus nephropathy and pregnancy 213
Table 3 (continued)
During pregnancy and postpartum
Urine
BUN/Creat prot. BP At Renal
Manifestations Serology mg/dI g/dav mm/Hg Rx delivery biopsy Comment
Sustained remission
Severe Act —/3.5 5.0 Pred TA 6/77 Exacerbation 1st trimester,
extrarenal Type III 1 mo followup: Creat 1.6 mgfdl;
Nephrotic 4/79 urine prot., 7.0 g/day
Renal failure Chronic ON
t BP Act 10/— 3.0 155 Pred FT
105
8/62
Inadequate
Partial remission,
Nephrotic syndrome
2 subsequent pregnancies
t BP — —/0.6 3+ 150 None FT
> 100
—
' BPandurineprot. in
3rd tnmester, followup 3 mo.
Fever Act —/4.3 1.0 150 Pred Premature — Persistent BP,
Arthritis 105 Alive Creat, 1.2 mg/dl,
Cerebritis Urine prot. 0.7 glday, 1979
Arthritis Inact 0/0.5 0.7 150 Pred FT
> 100
3/79
Type lila
Preeclampsia, onset proteinuria
postpartum, complete remission
1979
None — 0/1.0 1.2 None FT 12/69
Type III
Exacerbation postpartum
proteinuna and psychosis,
complete remission 1974
Arthritis — — — Chloro FT 1%!
Type III
Mild flare postpartum
Arthritis Act —/0.8 2+ 150 Pred FT
> 100
3/70
Type I
Mild flare with proteinuria
postpartum, mild
nonrenal 1979
ulonephritis, whereas the other patient experienced
only mild extra renal manifestations postpartum. A
third patient exhibited proteinuria during gestation
and was shown to have a type III lesion 8 months
after delivery. Renal biopsies performed shortly be-
fore conception or immediately after delivery in 4
patients revealed a type lila lesion in 2 cases and
type I histopathologic change in 2. Of these patients
with a proliferative glomerulonephritis, of mild to
moderate severity, the exacerbation involved mild
proteinuria in 3, but in the fourth reversible renal
failure and nephrotic syndrome occurred.
In summary, in the presence of complete clinical
remission of SLE of at 6 months, the outlook for a
live birth was reduced only slightly below the rate
expected in the normal population. Although ex-
acerbations occurred in 30% of pregnancies, signifi-
cant morbidity occurred in only about 10% of these
pregnancies, and in most patients there was a re-
versal of symptoms following delivery. It is impor-
tant to emphasize that these results were observed
in a group of patients with a 90% incidence of an-
tecedent lupus nephropathy. Moreover, in 12 pa-
tients, renal biopsy revealed a type III glomerulo-
nephropathy in the past history or near to the time
of gestation.
(2) SLE clinically active prior to conception. In
25 pregnancies, there was evidence of disease activ-
ity in the 6-month interval before conception. Clini-
cal manifestations remained unchanged in 10(40%),
improved in 3 (12%), and worsened in 12 (48%) dur-
ing pregnancy and postpartum as shown in Table 2.
In pregnancies associated with exacerbation, the in-
crease in SLE activity was noted during pregnancy
in 10 of 12 cases. The incidence of live births in this
group of pregnancies was 64%, after exclusion of
surgically interrupted pregnancies. In the remaining
8 pregnancies, fetal loss, either due to spontaneous
abortion, prematurity, or stillbirth, was probably at-
tributable to SLE activity or hypertension in at least
7 instances. In I pregnancy, the spontaneous abor-
tion at 7 weeks' gestation was within the expected
rate. Fetal loss due to SLE in this group of preg-
nancies, therefore, was approximately 32%. Signifi-
cant hypertension was recorded in 8 of 25 preg-
nancies.
Clinical data and results of renal biopsy in indi-
vidual pregnancies are shown in Table 4. Serologic
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Table 4. Summary of clinical data of women with SLE clinically active prior to conceptions
e
Past history
6 Months
Onset
preg. Manifestations Serology
before pregnancy
BUN/Creat
mg/dl
Urine
prot.
g/day Rx
.
Patient Manifestations Rx
Sustained activity
7 Severe Pred 5/74 Nephrotic, Act —/0.6 7.0 Pred
extrarenal Imur mild
Nephrotic activity
14 (1) Moderate Pred 7/74 Nephrotic — —/1.0 5.0 Pred
extrarenal
(2) Nephrotic 2/79 None,BP Inact —4.0 1.0 None
150/1 10
16 Moderate None 1/65 Moderate Inact —/0.9 2+ Chloro
extrarenal activity
Nephrotic
25 (1) Moderate Pred 9/69 BP 160/100 —/0.8 1.9 None
extrarenal
Nephrotic
Cr-2.0 mg/dl
31 Moderate Pred 1/78 None Inact —/1.0 2+ Pred
extrarenal Imur
Nephrotic
34 Moderate Pred 4/78 Onset Act —/1.3 1.0 Pred
extrarenal SLE
Prot 1.Og/d
35 Moderate Pred 5/77 Mild Inact —/0.8 <0.3 None
extrarenal activity
36 Severe Pred 6/77 None Act —/0.8 3.0 Pred
extrarenal Imur Imur
Nephrotic
39 Rash Pred 2/78 None Inact —/1.4 1.3 None
Nephrotic Imur
Exacerbation
3 Mild Pred 12/73 Mild Act —/0,9 <0.3 Pred
extrarenal Imur activity
4 Moderate Pred 2/73 Moderate —/1.0 Pred
extrarenal activity
Hematuria
Prot3.1 g/d
9 Moderate Pred 12/73 Moderate —/1.0 <0.3 None
extrarenal activity
10 Moderate Pred 5/73 Moderate Act 1+ Pred
extrarenal activity
Nephrotic
24 Mild Pred 4/71 None Act —/0.5 2+ None
extrarenal Imur
Prot 1.7g/d
13 Mild None 11/79 Mild —/0.9 <0.3 None
extrarenal activity
15 (3) Moderate Pred 10/77 Moderate Inact 13/0.8 <0.3 None
extrarenal activity
Prot 2-3+
28 Mild Pred 7/64 Onset Act — Pred
extrarenal SLE
33 Mild Pred 2/76 None —/2.0 — Pred
extrarenal
41(1) Moderate None 7/70 Moderate Act —/1.3 <0.3 Pred
extrarenal activity
46 Severe Pred 5/65 Onset Act —/1.2 4.4 Pred
extrarenal SLE
Nephrotic
6 Moderate Pred 3/74 Mild Inact — Pred
extrarenal Imur activity Imur
Prot 1.9g/d
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Table 4 (continued)
Pregnancy and postpartum
BP
mm/Hg Rx Delivery Renal BX CommentManifestations Serology
BUN/Creat
mg/dl
Urine
prot.
giday
Sustained activity
Nephrotic Inact —/0.9 12.0 150 Pred FT 6/69 Renal failure 1976,
too Type II dialysis 1979
Nephrotic — —/1.0 4.0 Pred TA 2/75
None Inact —/3.5 2.5 135 None SA Type II 4mofollowup:
ioo Creat 3.8 mgldl,
prot. 1.4 g/day
Moderate — 12/— 2+ Chloro FT 3/62 Remission, BUN 8 mg/dl,
activity Type II Prot 1+, 1970
None — —/0.6 1.1 None FT — Remissionofproteinuria
& subsequent preg.
None Inact 0/0.7 0.4 150 Pred FT 2/74 Persistent>
ioo Type III proteinuria, 1979
9/75
Type III
Moderate Act —/1.6 1.0 Pred SA 6/78 Material death
activity Type II Adrenal failure
Mild Act —/0.9 <0.3 Pred FT 5/79 Onset proteinuria
activity Type lIla 12 mo. after delivery
None Act —/1.4 3+ 130 Pred Stillbirth 1/76 1 mo. followupj Imur Type III
None Inact —/0.6 0.4 None FT 6/76 Persistent
Type III proteinuria, 1979
Exacerbation
Severe Act —/0.9 <0.3 Pred TA 3/73 Mild activity:
activity Type III Creat 1.9 mg/dl,
2/76 prot. 7.3 g/day, 1979
Type III
Nephrotic Act —/1.7 6.0 Pred FT 1967 Complete remission
Chioro Type lIla 1979
Nephrotic Act —/1.6 13.5 Pred FT None Persistent nephrosis
anemia 1979
Severe Act —/1.0 2.0 Pred FT None Persistent proteinuria
activity Imur 1979
Nephrotic Inact —/0.7 7.0 Pred FT None Partial remission nephrosis
1979
Thrombo- Act —/1.3 2.7 160 Pred Stillbirth None Persistant activity,
cytopenia 106 resolution of proteinuria 1979
Severe Inact —/0.8 <0.3 None FT 1961 Remission 1978
activity Type III
Nephrotic Act 60/— 6.0 Pred FT None Remission 1979
Renal — —/6.9 2.0 230 Pred Premature None 2 mo. followup
failure 130 death
Severe Act —/0.6 0.1 Pred Stillbirth 4/74 Transient prot 1974,
activity Type II remission 1979
Moderate Act —/22.0 >4.0 160 Pred Stillbirth 2/65 Maternal death
activity 105 Type III 4 mo. after delivery
Hypertension — 0/0.9 0.5 166 Pred FT 11/72 Remission 1979
108 Imur Type II
11/75
Type II
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Table 4 (continued)
Past history Onset
preg.
6 Months before pregnancy
Manifestations Serology
BUN/Creat
mg/dl
Urine
prot.
g/dav RxPatient Manifestations Rx
1 (1) Moderate Pred 1966
Remission
Onset Act 0/0.8 <0.3 Pred
extrarenal SLE
27 Moderate None 11/71 None Inact —/0.5 1.1 None
extrarenal
Nephiotic
47 Moderate Pred 11/76 Mild Inact —/0.9 <0.3 Pred
extrarenal Irnur activity
Prot 2+
Abbreviations are defined in Table 3.
studies were performed in 19 patients before onset
of pregnancy and, as in the previous group, corre-
sponded in general with the presence and activity of
SLE. Because there was a poor correlation between
the results of serologic tests and the course of dis-
ease activity during pregnancy and postpartum,
these studies did not provide a useful index for pre-
dicting the likelihood of exacerbation. Among the
10 pregnancies in which activity of disease re-
mained unchanged throughout pregnancy and post-
partum, a history of lupus nephropathy was present
in 9, and included nephrotic syndrome in 8 (1 pa-
tient also had exhibited reversible renal in-
sufficiency) and asymptomatic proteinuria in 1 pa-
tient. The single maternal death in this group of
pregnancies was attributed to adrenal failure due to
abrupt termination of glucocorticoid treatment.
Renal biopsy was performed in 9 of 10 cases. Each
of 3 patients with a type III lesion on biopsy 6
months or more before conception had persistent,
and unchanged, proteinuria and normal renal func-
tion during pregnancy. Five pregnancies in 4 pa-
tients were associated with a type II lesion. Protein-
uria, including nephrotic syndrome in 2 of these
pregnancies, and renal function were not affected
by pregnancy. Proteinuria first occurred approxi-
mately 1 year after delivery in 1 patient, and a type
lila lesion was demonstrated by biopsy.
One half of the pregnancies associated with ex-
acerbation exhibited signs of renal involvement be-
fore conception, and these included nephrotic syn-
drome in 2 patients and asymptomatic proteinuria in
the remaining patients. Three patients experienced
severe extrarenal signs of activity during or follow-
ing pregnancy, and in 9 pregnancies, exacerbation
was characterized by manifestations of lupus ne-
phropathy, including nephrotic syndrome in 5 preg-
nancies; in 2 of these pregnancies renal failure also
occurred. Renal biopsies were performed in 6 of 12
patients and revealed a type III lesion in 3, a type II
lesion in 2, and in the remaining patient a type lila
injury pattern. One maternal death was recorded in
a patient with onset of SLE within 6 months of ges-
tation and a progressively deteriorating course. In
11 patients followed beyond a few months after de-
livery, there was a reversal of the exacerbation,
both of extrarenal and renal manifestations, in 8 in-
stances.
Three patients demonstrated an amelioration of
activity after onset of pregnancy; in 2 patients there
were extrarenal signs of activity before conception,
and in 1 patient proteinuria was present. Renal
biopsy demonstrated a type III lesion prior to gesta-
tion in 1 patient and types III and lila in the other
cases at a later time. Complete clinical remission
persisted after delivery in all 3 patients.
In summary, the course of pregnancy was more
problematic in cases with ongoing signs of activity
through the time of conception. The likelihood of a
live birth was approximately 65%, and there was
nearly a 50% rate of exacerbation. Although ex-
acerbation and hypertension tended to be more se-
vere in these pregnancies than they were in the pre-
vious group, most patients experienced clinical im-
provement following delivery.
Onset of SLE during pregnancy or postpartum.
The onset of SLE occurred during pregnancy or
postpartum in 9 patients. A summary of these cases
is shown in Table 5. Signs of lupus nephropathy
were found at onset in 5 patients, but in the remain-
ing 4 patients renal involvement became evident at
a later time during followup. Excluding the single
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Table 4 (continued)
Pregnancy and postpartum
Urine
BUN/Creat prot. BP
Manifestations Serology mg/dl g/day mm/Hg Rx Delivery Renal BX Comment
Remission
None — 0/0.7 <0.3 Pred SA 10/73 Remission 1979
Type lila
None Act 0/0.5 0.2 None FT 3/74 Remission 1979
Type III
None — 0/0.8 <0.3 Pred TA 10/72 Remission 1978
Type Ill
10/74
Type I
therapeutic abortion, the incidence of live births Discussion
was 63%. The rate of fetal loss due to the con- The influence of pregnancy on the natural course
currence of SLE and pregnancy was approximately of SLE and of SLE on the outcome of pregnancy
25% (a still birth and I spontaneous abortion at 24 have not been established. Although reports on
weeks). There was 1 death in this group of preg- small series of patients with SLE have tended to
nancies, involving a patient who had persistent din- emphasize a high maternal complication rate during
ical activity and died of pancreatitis 18 months after pregnancy and a reduced likelihood of a successful
delivery. Despite the relatively severe initial mani- outcome for the product of conception [7, 9, 17],
festations of SLE in the remaining patients, clinical reports on large series, including a wider spectrum
remission occurred in 7 patients, and 5 had sub- of disease severity, have not supported these con-
sequent pregnancies. Renal biopsies were per- clusions [1-4]. Although it is clear from previous
formed in all but 1 patient and revealed a type III studies that patients with clinical evidence of active
lesion within 6 months of delivery in 5 patients. In 3 SLE at onset of gestation often experience a hectic
patients the underlying lesion was identified a year course during pregnancy and postpartum [1, 4, 11],
or more later, and demonstrated a type III lesion in such occurrences have not been distinguished from
2 and a type lila lesion in 1 patient. the unpredictable natural course of active SLE.
Table 5. Onset of SLE during pregnancy or postpartuma
Urine
Onset Extrarenal BUN/Creat protein BP
Patient preg. Onset SLE manifestations mg/dl g/day mm/Hg RX Del. Renal BX Subsequent pregnancies
17 1/65 1st trimester Heart failure —/0.6 <0.3 Pred TA 3/79, Type lIla 3/79, mild exacerbation
18 12/62 Postpartum Arthritis, fever —/0.3 0.2 Pred SA 8/73, Type III 12/74, FT, uncomplicated
lympha- 5/77, FT, uncomplicated
denopathy
20 12/76 Postpartum Fever, pleuritis —/3.7 12.0 None SA 6/77, Type III 1978, SA, uncomplicated
hematuria 4/79, Type lila 2/79, SA, uncomplicated,
Creat, 3.5 mg/dl
23 6/62 2nd trimester Abdominal —/1.0 2+ 110 None Premat, 3/63, Type III None, maternal death, 18
pain, live mo. due to pancreatitis
jaundice
26 12/74 3rd trimester Neophrotic —/0.8 7.0 Pred FT 1/75, Type III None, complete
remission 1979
27 7/73 2nd trimester Nephrotic —/1.7 10.0 Pred Stillbirth 3/74, Type III 3/77, FT, uncomplicated
32 7/78 2ndtrimester Nephrotic, —/1.5 9.0 Pred FT None None, shortfollowup
arthritis
41 3/66 Postpartum Arthritis —/1.3 <0.3 150 None FT 12/71, Type III 7/70, stillbirth, remission
4/74, Type II 1979
44 5/70 lsttnmester Arthritis, —/1.0 4.0 None FT 5/71,TypeIII None,partialremission
nephrotic 3 mo. postpartum
a Abbreviations are defined in Table 3.
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Moreover, in regards to the contemporary manage-
ment of patients with SLE, as modified by treat-
ment, it is important to recall that in many of the
initial reports on the relationship between SLE and
pregnancy, treatment with glucocorticoids and/or
cytotoxic agents were not routinely available or
used [1,2,4, 8].
The relationship between pregnancy and lupus
nephropathy is also unclear. Previous studies have
indicated improvement, no change, or worsening in
the course of lupus nephropathy during gestation
[1-4, 6—11, 17—19]. There are few details, however,
on the nature of the renal lesions, the time sequence
between onset of renal disease and pregnancy, and
the characteristics of renal function before onset of
pregnancy. An evaluation of this relationship is also
complicated by the potential influence of renal dis-
ease, itself, in the absence of SLE, on fetal develop-
ment and normal physiologic changes of pregnancy.
The patients in this survey provide an important
source of case material for evaluation of the effect
of pregnancy on lupus nephropathy. In nearly 80%
of subjects, the onset of lupus nephropathy ante-
dated conception or occurred concurrently with
gestation. In the remaining patients, renal in-
volvement became clinically evident during a sub-
sequent stage of their illness. In addition, informa-
tion on the nature of the renal lesion was available
in 77% of patients, and clinical manifestations of
renal disease were moderately severe in the major-
ity of cases. Before and/or during pregnancy, the
nephrotic syndrome occurred in 26 patients, and
overt renal insufficiency, on the basis of a serum
creatinine value above 1.5 mg/dl, was present in a
total of 13 subjects. It seems likely, therefore, that
these patients represent a high-risk group for the
potential of complications during pregnancy be-
cause of the concurrence of renal disease, as well as
the presence of SLE.
It is clear from this analysis that neither SLE nor
a history of lupus nephropathy exclude a successful
pregnancy. Despite clinical evidence for antecedent
renal disease in most patients in this series, and a
high incidence of severe histopathologic changes by
renal biopsy, the activity of SLE was apparently
not influenced by pregnancy in nearly two thirds of
the cases. Moreover, in pregnancies that occurred
after the onset of SLE, including those immediately
preceded by active SLE and/or persistent signs of
lupus nephropathy, the rate of fetal wastage due to
SLE was only approximately 20%.
Among the 56 pregnancies that followed the onset
of SLE, an important determinant of the course of
SLE during pregnancy and postpartum, and of the
outcome of pregnancy, was evidence of complete
clinical remission of at least 6 months' duration be-
fore conception. In these pregnancies, remission
persisted in two thirds, severe reversible ex-
acerbations occurred in 10%, and the rate of suc-
cessful live births of 92% was comparable to that
reported by Ferris [20] and Strauch and Hayslett
[21] in normotensive gravidas with other diverse
types of renal parenchymal disease. The occurrence
of pregnancy in patients with ongoing signs of SLE
activity and/or renal disease was associated with a
more hectic course during pregnancy and post-
partum, as expected, and a successful outcome was
reduced by 25%. In this group of pregnancies, how-
ever, it seems likely that the recorded incidence of
exacerbation overestimates to some extent the ad-
verse effect of pregnancy on the course of SLE. It is
possible, for example, that worsening of disease ac-
tivity was consistent with the natural variation of
disease activity in some patients, and that an in-
crease in urinary protein excretion, classified as ex-
acerbation, did not, in fact, reflect an increase in
SLE activity or an intrinsic change in the renal le-
sion in all cases. Previous studies have suggested
that the rate of protein excretion in patients with
preexisting proteinuria may increase transiently
during pregnancy without an alteration in the natu-
ral history of the renal disease [21]. In 5 of 12 preg-
nancies characterized by proteinuria during 6
months prior to conception and classified as exhib-
iting an exacerbation, protein excretion rose during
pregnancy, in the absence of systemic activity, and
remitted completely, or partially, after delivery. In
summary, therefore, it seems likely that the calcu-
lated rate of exacerbation in patients with signs of
SLE activity and/or renal disease immediately be-
fore conception overestimates the actual rate of
change in activity of SLE.
In agreement with previous reports the onset of
SLE during pregnancy or postpartum caused signif-
icant maternal morbidity and a fetal loss of approxi-
mately 37%. There was no evidence, however, that
the subsequent course of the patients was different
from the course expected in the absence of preg-
nancy, and 5 of 9 patients with this occurrence ex-
perienced subsequent uncomplicated pregnancies.
A total of 16 pregnancies were complicated by the
nephrotic syndrome. lt was of interest, therefore, to
analyze these pregnancies independently of the as-
sociated SLE activity. If the single nonindicated in-
duced abortion is excluded, there were 9 full-term
live births among 10 nephrotic gravidas with a
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serum creatinine value of 1.5 mg/dl or less. In con-
trast, there were only 2 successful outcomes among
5 uninterrupted pregnancies in patients with neph-
rotic syndrome and renal insufficiency. These data
are in agreement with the analysis of Lindheimer
and Katz [22] that indicates a good prognosis for the
nephrotic syndrome in pregnancy, provided that
hypertension is absent and renal function is ade-
quate.
In a separate analysis of 10 noninterrupted preg-
nancies in patients with a serum creatinine value of
1.5 mg/dl or more, including patients with and with-
out nephrotic syndrome, the fetal loss was 50%. Of
the 5 live births in this group, it was of interest that
the serum creatinine was 4.0 mg/dl or more during
pregnancy in 3 patients, indicating that a successful
outcome may occur occasionally despite severe
renal failure.
An important interest in this study was the corre-
lation of the renal lesion by biopsy with the clinical
course during pregnancy. There is substantial evi-
dence that subendothelial deposits (type III), an ul-
trastructural change usually associated with a more
intense intraglomerular proliferative lesion, reflect a
more aggressive form of lupus nephropathy com-
pared with lesions with no deposits (type I), sub-
epithelial deposits (type II), or deposits localized to
the mesangial region (type lIla) [23, 24]. In the pres-
ent study, there were 18 patients with a type III le-
sion on the initial renal biopsy, performed either be-
fore gestation or postpartum. Renal insufficiency
occurred in 2 of these patients. Under the same con-
ditions, there were 6 patients with a type lila lesion,
7 with a type II pattern, and 3 with type I, and renal
function remained normal in all patients. Following
biopsy, with the exception of 2 patients, treatment
was instituted in the form of prednisone alone or in
combination with a cytoxic agent.
Although there was no apparent correlation be-
tween the type of renal lesion and the subsequent
level of renal function, it is possible that the pattern
of glomerular injury was changed, due to treatment,
in patients with a type III lesion on the initial
biopsy. A previous study by Hecht et al demon-
strated a transformation from type III to lesions of
the type I or type II variety in 20 of 31 patients
treated with prednisone and azathioprine for at least
2 years [13]. In the present study, serial biopsies
were performed in 10 patients with a type III lesion
on the initial study. In these cases, there was a sub-
sequent transformation to either type II, lila, or I in
7 patients, no change in 2, and a change to chronic
glomerulonephritis without deposits in 1 patient.
Renal biopsy was performed in 4 patients in whom
SLE first occurred during pregnancy or post-
partum, and a type III lesion was identified in all
cases. Renal function was reduced in 2 patients and
was normal in 2.
It seems likely, therefore, that the histopatholog-
ic pattern of injury found by biopsy in many pa-
tients in this series may not have represented the
actual type of renal lesion during gestation, because
the procedure was most often performed 6 months
to several years before pregnancy. In our view,
however, information derived from renal biopsy
provides useful data in the assessment of the type
and severity of renal involvement and should be
used in the evaluation of patients with SLE who are
considering the possibility of pregnancy. Future
studies will be necessary to confirm the validity of
this approach.
Finally, in this series of pregnancies and in each
of the papers cited in this report, there is no evi-
dence that use of glucocorticoids or cytotoxic
agents induced developmental anomalies in the off-
spring of women treated during pregnancy, in
agreement with the results obtained in patients with
renal homografts treated with similar drugs [25].
Because complete suppression of SLE activity in-
creases the likelihood of an uncomplicated preg-
nancy, appropriate treatment should not be with-
held from women with SLE who become pregnant.
The data available in this series of patients was in-
adequate to determine whether an increase in ste-
roid therapy postpartum reduced the incidence of
exacerbations after delivery or has a role in the
management of patients with SLE.
Conclusion. The data indicate that a history of
lupus nephropathy does not preclude an outlook for
a successful pregnancy in patients with SLE. Com-
plete clinical remission for at least 6 months in-
dicates a favorable prognosis for an uncomplicated
course during pregnancy and a live birth, even in
individuals with severe histopathologic changes by
renal biopsy and heavy proteinuria in the early
stage of their disease. Continued signs of disease
activity or renal disease reduce, however, the likeli-
hood for an uncomplicated pregnancy, although
persistent proteinuria alone may not represent more
of a risk factor than it does in other types of renal
disease. The incidence of exacerbation in the pres-
ent series was not greater postpartum than during
pregnancy, as suggested in previous reports. These
data indicate, therefore, that generalized con-
clusions about the prospects of pregnancy should
not be made in patients with SLE without consid-
220 Hays/eu and Lynn
eration of individual features of disease activity and
the risk factors suggested by this study.
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